GPT and Hepatic fibrosis: Our meta‐analysis builds on existing RCTs studies and focuses on key outcomes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, low density lipoprotein (LDL) and high density lipoprotein (HDL) levels, liver fat reduction (MRI‐PDFF), adverse events, serious adverse events, enhanced liver fibrosis (ELF), adiponectin, and MASH resolution with no worsening of fibrosis to offer a comparative perspective to shape future treatment options.